Polymorphisms in the BER and NER pathways can also significantly affect the effectiveness of gynecological cancer therapies using PARP (Poly (ADP-ribose) polymerase) inhibitors, such as olaparib, niraparib, or rucaparib [100,101]. Here, PARP1 is linked to female reproductive organ cancer.